Abstract
Pancreatic adenocarcinoma has repetitively proved refractory to chemotherapy and biologic compounds with only a few drugs offering limited benefit. A number of novel regimens has been tested in phase I trials and reported recently in the 2011 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium. Specifically, a novel mitogen-activated protein kinase kinase (MEK) inhibitor, a connective tissue growth factor inhibitor, a coagulase factor VIIa inhibitor, as well as adenovirus delivery of herpes simplex virus thymidine synthase gene followed by anti-herpetic treatment have all proven to be safe in pancreatic cancer patients. Phase II trials will provide further evidence whether they can become clinically relevant in the future.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / pathology
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Clinical Trials, Phase I as Topic
-
Connective Tissue Growth Factor / immunology
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Enzyme Inhibitors / administration & dosage
-
Factor VIIa / antagonists & inhibitors
-
Factor VIIa / metabolism
-
Gemcitabine
-
Humans
-
MAP Kinase Kinase 1 / antagonists & inhibitors
-
MAP Kinase Kinase 1 / metabolism
-
MAP Kinase Kinase 2 / antagonists & inhibitors
-
MAP Kinase Kinase 2 / metabolism
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / pathology
-
Pyridones / administration & dosage
-
Pyrimidinones / administration & dosage
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Anticoagulants
-
CCN2 protein, human
-
Enzyme Inhibitors
-
Pyridones
-
Pyrimidinones
-
Deoxycytidine
-
Connective Tissue Growth Factor
-
trametinib
-
MAP2K2 protein, human
-
MAP Kinase Kinase 1
-
MAP Kinase Kinase 2
-
MAP2K1 protein, human
-
Factor VIIa
-
pamrevlumab
-
Gemcitabine